5509349550-53e25f28b9-z-1
© GSK
24 February 2015Americas

Novartis, FTC agreement paves way for $16bn buyout of GSK’s cancer unit

Swiss pharmaceutical company Novartis can buy London-based GlaxoSmithKline’s (GSK) portfolio of cancer drugs after it agreed to meet certain conditions set by the US Federal Trade Commission (FTC), the agency has said.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
20 December 2018   Pharmaceutical companies GSK and Pfizer yesterday announced that they will combine their consumer health businesses into a new joint venture with sales of approximately £9.8 billion ($12.7 billion).

More on this story

Americas
20 December 2018   Pharmaceutical companies GSK and Pfizer yesterday announced that they will combine their consumer health businesses into a new joint venture with sales of approximately £9.8 billion ($12.7 billion).

More on this story

Americas
20 December 2018   Pharmaceutical companies GSK and Pfizer yesterday announced that they will combine their consumer health businesses into a new joint venture with sales of approximately £9.8 billion ($12.7 billion).